🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happening now: An all 🌟 panel of experts is sharing insights on precision medicine and the evolving landscape of bladder cancer care at #AUA2025 Sia Daneshmand, M.D. Laura Bukavina Sarah P. Psutka MD MS Matt Galsky PeerView Bladder Cancer Advocacy Network

Bernie Bochner, MD Ashish M. Kamat, MD, MBBS Shilpa Gupta Bladder Cancer Advocacy Network Matt Galsky Sia Daneshmand, M.D. Sia Daneshmand, M.D. Bladder preservation after clinical CR to NAC: Not ready for prime time. We haven’t figured out clinical and radiologic staging. #AUA25 IBCG Amer. Urol. Assn. Mark Tyson Alexander Kutikov MD Kent Mouw Joshua Meeks Matt Galsky

Proud of the research team for all their presentations. Mazyar (Menachem) Zahir, M.D. Chirag Doshi Domenique Escobar, MD 👩🏽‍⚕️🧜🏽‍♀️ Leilei Xia

A well-deserved honor for one of the very best. A true leader in our field and an even better human Congrats my friend! Bernie Bochner, MD Society of Urologic Oncology #AUA25 The Society of MSKCC

Couldn’t agree more. My inspiration for entering urologic oncology when I was a resident. Congratulatjons Bernie Bochner, MD for this well deserved honor.

Clinical Complete Response to NAC- Ready for Prime Time? urotoday.com/conference-hig… via UroToday.com Matt Galsky Bernie Bochner, MD Ashish M. Kamat, MD, MBBS Zach Klaassen IBCG Bladder Cancer Advocacy Network Petros Grivas SWOG Cancer Research Network Trinity J. Bivalacqua Andrea Necchi Mark Tyson Leslie Ballas Shilpa Gupta Kent Mouw Joshua Meeks

Totally agree! Leslie Ballas Mark Tyson Abhishek Tripathi Bladder Cancer Advocacy Network

This is a cool graph

Registry data shows risk migration with blue light cystoscopy. Alireza Ghoreifi, MD Duke Urology & Sia Daneshmand, M.D. Keck School of Medicine of USC sit down with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to highlight the blue light cystoscopy registry's value as an ongoing real-world database with over 3,000

📺 Dr. Sia Daneshmand, M.D. moderates a new roundtable series featuring guest panelists Mark Tyson, Aaron Berger, MD, of Associated Urological Specialists, and Vignesh Packiam, MD discussing the evolving treatment and diagnostic landscape of #NMIBC: buff.ly/UbJobkE ⭐ In part 1, the panelists

⭐ Drs. Neal Shore and Sia Daneshmand, M.D. discuss a practice-changing research update presented by Dr. Shore at #AUA25 related to #sasanlimab plus #BCG for high-risk non-muscle invasive #bladdercancer: buff.ly/aDkaNk2 👉 Results of the CREST study show that sasanlimab in

It was such an honor to be the visiting professor Penn State Urology. Thank you to Jay Raman, and the amazing faculty, staff and residents for the warm hospitality.

Real-world data improves #NMIBC risk assessment with blue light technology. Sia Daneshmand, M.D. Keck Medicine of USC & Boris Gershman BIDMCUrology join Sam S. Chang MD, MBA Vanderbilt Urology to unveil a new risk model using blue light cystoscopy data. Built from a 1,100-patient registry, it predicts

Honored to join the editorial board of Urologic Oncology as Social Media Editor. Grateful to Dr. Maranchie and Dr. Mark Ball, MD, FACS for their trust. I look forward to helping expand the reach of this esteemed journal across social media platforms. YUO Society of Urologic Oncology Elsevier

Amazing Alireza. Congratulations. Well deserved honor.

Bladder cancer care is evolving fast! From NMIBC to mUC, learn more with Drs. Sia Daneshmand (Sia Daneshmand, M.D.), Laura Bukavina (@laurabukavinamd), Matthew D. Galsky (Matt Galsky), & Sarah P. Psutka, MD, MS, FACS (Sarah P. Psutka MD MS)! bit.ly/3FnjP23 PeerView

ABLE-22: safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy in BCG-unresponsive #NMIBC—a randomized, open-label, phase 2 study. Presented by Sia Daneshmand, M.D. Keck Medicine of USC. #ASCO25 written coverage by Rashid K. Sayyid

FDA approves UGN-102, mitomycin intravesical solution (ZUSDURI™ ) for Recurrent Low-Grade IR NMIBC businesswire.com/news/home/2025… UroGen Pharma Roger Li Sia Daneshmand, M.D. Max Kates IBCG Joan Palou Redorta

Excited to share our Valar Labs publication in European Urology validating Vesta Risk Stratify computational histology AI biomarkers to predict recurrence and progression in High Grade Ta Bladder Cancer. (1/5) Publication: authors.elsevier.com/c/1lFoD14kpm0h…

A true honor to serve as VP Rutgers RWJ Urology. Incredible division led by empowering Thomas Jang with star faculty Saum Ghodoussipour Vignesh Packiam, MD David Golombos RoboUroMD Chrystal Chang, MD Danielle Leitner. Excited for future of stunning new Rutgers Cancer Institute Center. Thx to all residents for